Compare STEM & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STEM | MXCT |
|---|---|---|
| Founded | 2009 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.3M | 80.1M |
| IPO Year | 2020 | 2021 |
| Metric | STEM | MXCT |
|---|---|---|
| Price | $9.42 | $0.79 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $13.33 | $5.50 |
| AVG Volume (30 Days) | 107.0K | ★ 932.5K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $156,266,000.00 | $33,026,000.00 |
| Revenue This Year | $3.43 | N/A |
| Revenue Next Year | $13.92 | $18.89 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 8.08 | N/A |
| 52 Week Low | $0.29 | $0.64 |
| 52 Week High | $32.23 | $2.96 |
| Indicator | STEM | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 45.01 | 54.59 |
| Support Level | $8.12 | $0.75 |
| Resistance Level | $10.99 | $0.87 |
| Average True Range (ATR) | 0.71 | 0.05 |
| MACD | 0.15 | 0.01 |
| Stochastic Oscillator | 48.43 | 84.23 |
Stem Inc is a provider of energy storage systems. The company bundles third-party hardware with its proprietary Athena software to provide customers a turnkey solution. Stem sells its solutions to commercial and industrial customers as well as independent power producers and renewable developers. Its solutions help customers maximize renewable energy generation and help build a cleaner and more resilient grid. The Company operates as one operating segment that is focused exclusively on technology services that transform the way energy is distributed and consumed.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.